EF
KYMR icon

Empowered Funds’s Kymera Therapeutics KYMR Stock Holding History

Empowered Funds’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
2,338
-100
-4% -$8.59K ﹤0.01% 1900
2026
Q1 		$203K Buy
+2,438
New +$193K ﹤0.01% 2018

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Empowered Funds's KYMR Position: Q2 2026 in Review

Empowered Funds reduced its Kymera Therapeutics (KYMR) stake by 4.1% in Q2 2026, selling an estimated $8.59K and leaving 2,338 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Empowered Funds first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Empowered Funds held 2,338 shares of Kymera Therapeutics worth $268K as of Q2 2026.
  • Empowered Funds sold 100 Kymera Therapeutics shares in Q2 2026, an estimated $8.59K.
  • Kymera Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1900 holding.
  • Empowered Funds first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.